There is the need for complementary tools capable of restoring intestinal balance in the long term in patients with digestive diseases.
The prebiotic of GoodGut, with beneficial properties for patients with IBD and IBS, is a non-digestible fiber which has been developed to induce the selective growth of the protective bacteria. This increases their immunoprotective activity, such as the production of volatile fatty acids. In addition, it provides several advantages compared to probiotics:
PREVIPECT has been assessed in a pilot study with fecal samples from 18 patients with IBD, IBS, and health subjects. The study consisted of evaluating the effect of the prebiotic on the fecal microbiota. It was carried out in collaboration with Hospital Universitari de Girona Dr. Josep Trueta. In addition, we completed the In Vitro toxicity test. For more information, you can check the results published in the study here (Oliver L. et al, 2021).
In order to validate the results observed in the pilot study, and demonstrate the benefits and added value of PREVIPECT in subjects with intestinal diseases such as IBD or IBS, the next step is to conduct clinical trials with the different target populations. With this, we plan to launch the product to the market in 2022.